Show simple item record

dc.contributor.authorKohlhoff, S A
dc.contributor.authorRoblin, P M
dc.contributor.authorReznik, T
dc.contributor.authorHawser, S
dc.contributor.authorIslam, K
dc.contributor.authorHammerschlag, M R
dc.date.accessioned2023-07-05T16:11:55Z
dc.date.available2023-07-05T16:11:55Z
dc.date.issued2004-05
dc.identifier.citationKohlhoff SA, Roblin PM, Reznik T, Hawser S, Islam K, Hammerschlag MR. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob Agents Chemother. 2004 May;48(5):1885-6. doi: 10.1128/AAC.48.5.1885-1886.2004. PMID: 15105151; PMCID: PMC400585.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid15105151
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10367
dc.description.abstractThe in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC(90) and MBC(90)) were 0.5 micro g/ml, compared to an azithromycin MIC(90) and MBC(90) of 0.125 micro g/ml and levofloxacin MIC(90)s and MBC(90)s of 1 micro g/ml for C. trachomatis and 0.5 micro g/ml for C. pneumoniae.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epub/10.1128/aac.48.5.1885-1886.2004en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume48
dc.source.issue5
dc.source.beginpage1885
dc.source.endpage6
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-07-05T16:11:55Z
html.description.abstractThe in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC(90) and MBC(90)) were 0.5 micro g/ml, compared to an azithromycin MIC(90) and MBC(90) of 0.125 micro g/ml and levofloxacin MIC(90)s and MBC(90)s of 1 micro g/ml for C. trachomatis and 0.5 micro g/ml for C. pneumoniae.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue5en_US


Files in this item

Thumbnail
Name:
aac.48.5.1885-1886.2004.pdf
Size:
35.98Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International